EMA Grants Orphan Drug Designation to Vanda’s Imsidolimab for Rare Psoriasis — Vanda Pharmaceuticals Inc.

Event summary

The EMA’s Committee for Orphan Medicinal Products recommended orphan drug designation for Vanda Pharmaceuticals’ imsidolimab to treat generalized pustular psoriasis (GPP).
This is the first time GPP has been recognized as a distinct rare disease in the EU under this designation.
Imsidolimab, an IL-36 receptor inhibitor, targets a chronic, life-threatening skin condition affecting fewer than 5 in 10,000 people in the EU.
The FDA is reviewing imsidolimab’s Biologics License Application (BLA) with a target action date of December 12, 2026.

The big picture

Vanda Pharmaceuticals’ EMA designation for imsidolimab underscores the growing recognition of generalized pustular psoriasis as a distinct rare disease. This regulatory milestone follows similar approvals in the U.S. and Japan, positioning Vanda to capitalize on unmet medical needs in a niche but critical segment of dermatology. The FDA’s pending decision will further determine the drug’s global market potential.

What we're watching

Regulatory Momentum: Whether the EMA’s designation will accelerate imsidolimab’s approval and commercialization in Europe.
Clinical Validation: How upcoming FDA decisions on December 12, 2026, could validate or challenge imsidolimab’s therapeutic potential.
Market Exclusivity: The extent to which orphan drug benefits, including market exclusivity, will strengthen Vanda’s competitive position in GPP treatment.